1094 related articles for article (PubMed ID: 33939590)
1.
Chandel V; Tripathi G; Nayar SA; Rathi B; Kumar A; Kumar D
J Biomol Struct Dyn; 2022; 40(19):8850-8865. PubMed ID: 33939590
[TBL] [Abstract][Full Text] [Related]
2.
Maurya AK; Mishra N
J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
[TBL] [Abstract][Full Text] [Related]
3. Molecular insights to the binding interactions of APNS containing HIV-protease inhibitors against SARS-CoV-2 M
Purohit P; Dash JJ; Muya JT; Meher BR
J Biomol Struct Dyn; 2023 Jun; 41(9):3900-3913. PubMed ID: 35388744
[TBL] [Abstract][Full Text] [Related]
4. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants -
Shree P; Mishra P; Selvaraj C; Singh SK; Chaube R; Garg N; Tripathi YB
J Biomol Struct Dyn; 2022 Jan; 40(1):190-203. PubMed ID: 32851919
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.
Abdizadeh R; Hadizadeh F; Abdizadeh T
J Biomol Struct Dyn; 2023; 41(13):5915-5945. PubMed ID: 35848354
[TBL] [Abstract][Full Text] [Related]
6. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL
Koulgi S; Jani V; Uppuladinne M; Sonavane U; Nath AK; Darbari H; Joshi R
J Biomol Struct Dyn; 2021 Sep; 39(15):5735-5755. PubMed ID: 32679006
[TBL] [Abstract][Full Text] [Related]
7. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
Ancy I; Sivanandam M; Kumaradhas P
J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689
[TBL] [Abstract][Full Text] [Related]
8. Virtual screening of natural products inspired in-house library to discover potential lead molecules against the SARS-CoV-2 main protease.
Garg A; Goel N; Abhinav N; Varma T; Achari A; Bhattacharjee P; Kamal IM; Chakrabarti S; Ravichandiran V; Reddy AM; Gupta S; Jaisankar P
J Biomol Struct Dyn; 2023 Mar; 41(5):2033-2045. PubMed ID: 35043750
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of multiple SARS-CoV-2 proteins by an antiviral biomolecule, seselin from
Nivetha R; Bhuvaragavan S; Muthu Kumar T; Ramanathan K; Janarthanan S
J Biomol Struct Dyn; 2022; 40(21):11070-11081. PubMed ID: 34431451
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 M
Bharadwaj S; Azhar EI; Kamal MA; Bajrai LH; Dubey A; Jha K; Yadava U; Kang SG; Dwivedi VD
J Biomol Struct Dyn; 2022 Apr; 40(6):2769-2784. PubMed ID: 33150855
[TBL] [Abstract][Full Text] [Related]
11. Repurposing drugs and identification of inhibitors of integral proteins (spike protein and main protease) of SARS-CoV-2.
Shode FO; Idowu ASK; Uhomoibhi OJ; Sabiu S
J Biomol Struct Dyn; 2022 Sep; 40(14):6587-6602. PubMed ID: 33590806
[TBL] [Abstract][Full Text] [Related]
12.
El-Hddad S; Sobhy M; Ayoub A; El-Adl K
J Biomol Struct Dyn; 2023 Nov; 41(19):9267-9281. PubMed ID: 36399002
[TBL] [Abstract][Full Text] [Related]
13. Molecular Binding Mechanism and Pharmacology Comparative Analysis of Noscapine for Repurposing against SARS-CoV-2 Protease.
Kumar N; Sood D; van der Spek PJ; Sharma HS; Chandra R
J Proteome Res; 2020 Nov; 19(11):4678-4689. PubMed ID: 32786685
[TBL] [Abstract][Full Text] [Related]
14. Identification of doxorubicin as a potential therapeutic against SARS-CoV-2 (COVID-19) protease: a molecular docking and dynamics simulation studies.
Sajid Jamal QM; Alharbi AH; Ahmad V
J Biomol Struct Dyn; 2022 Oct; 40(17):7960-7974. PubMed ID: 33826483
[TBL] [Abstract][Full Text] [Related]
15. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease.
Fadaka AO; Sibuyi NRS; Martin DR; Klein A; Madiehe A; Meyer M
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502340
[TBL] [Abstract][Full Text] [Related]
16. Targeting SARS-CoV-2 main protease: structure based virtual screening, in silico ADMET studies and molecular dynamics simulation for identification of potential inhibitors.
Uniyal A; Mahapatra MK; Tiwari V; Sandhir R; Kumar R
J Biomol Struct Dyn; 2022 May; 40(8):3609-3625. PubMed ID: 33226303
[TBL] [Abstract][Full Text] [Related]
17. Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target.
Kundu D; Selvaraj C; Singh SK; Dubey VK
J Biomol Struct Dyn; 2021 Jun; 39(9):3428-3434. PubMed ID: 32362243
[TBL] [Abstract][Full Text] [Related]
18. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
[TBL] [Abstract][Full Text] [Related]
19. Identification of bioactive molecule from
Tripathi MK; Singh P; Sharma S; Singh TP; Ethayathulla AS; Kaur P
J Biomol Struct Dyn; 2021 Sep; 39(15):5668-5681. PubMed ID: 32643552
[TBL] [Abstract][Full Text] [Related]
20. In silico analysis and identification of promising hits against 2019 novel coronavirus 3C-like main protease enzyme.
Chatterjee S; Maity A; Chowdhury S; Islam MA; Muttinini RK; Sen D
J Biomol Struct Dyn; 2021 Sep; 39(14):5290-5303. PubMed ID: 32608329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
